Background: Inflammatory bowel disease (IBD) adversely impacts the quality of life. Healthcare professionals target treatment at controlling gut inflammation. However, patients report troublesome symptoms of fatigue, abdominal pain and urgency or faecal incontinence in the absence of inflammation. Objectives: To address the symptoms of fatigue, pain and urgency/faecal incontinence in people living with inflammatory bowel disease. Research questions: Identifying the burden of symptoms: 1a. What proportion of people with inflammatory bowel disease have fatigue, pain or urgency/faecal incontinence and want help for them? 1b. Which symptoms could benefit from optimisation of medical treatment? Addressing symptoms: 2a. To develop and test a supported tailored online self-management programme (IBD-BOOST) for these symptoms in inflammatory bowel disease to improve the quality of life and reduce symptoms. 2b. Does better symptom control reduce healthcare and personal costs and is the intervention cost-effective? Design and methods: Qualitative interviews with patients and nurses. Questionnaire to identify the inter-relationship of symptoms and the desire for intervention. Feasibility study of a checklist and algorithm (‘Optimise’) to manage medically reversible causes of symptoms. Multicentre, two-arm, parallel-group, randomised controlled trial of the IBD-BOOST intervention with qualitative and quantitative process evaluation. Target population: 740 people with inflammatory bowel disease recruited from the questionnaire survey. Six months of access to IBD-BOOST was compared with care as usual. Setting and participants: United Kingdom inflammatory bowel disease clinics and online. Interventions: Randomised controlled trial – a 12-session online self-management IBD-BOOST intervention, developed jointly with patients. Main outcome measures: Primary outcomes for randomised controlled trial: United Kingdom Inflammatory Bowel Disease Questionnaire (inflammatory bowel disease-related quality of life) and Global Rating of Symptom Relief at 6 months. Cost-effectiveness of IBD-BOOST was assessed: incremental cost per quality-adjusted life-year 1 year following randomisation from healthcare service and societal perspectives. Results: Interviews: People with inflammatory bowel disease told us that they wanted help to self-manage their symptoms. Inflammatory bowel disease nurses wanted to be supportive but reported limited capacity to help. Survey: There were 8486 responses: 3281 men and 4883 women. In the previous week, 2550 (30%) reported fatigue; 1766 (21%) pain and 4565 (54%) reported faecal incontinence; 925 (10.9%) reported all three; 56% of all respondents ‘definitely’ wanted help for fatigue; 42% wanted help for pain; 53% wanted help for incontinence and 29% ‘definitely’ wanted help for all three symptoms. Feasibility study of the optimise checklist and algorithm: The 201/515 (39%) individuals reporting symptoms consented and 194/201 (97%) returned the symptom checklist; 157 (81%) returned a postal faecal calprotectin sample. The algorithm suggested at least one clinical test or intervention for fatigue, pain or incontinence in 67/157 (43%) participants, of whom 25 (37%) declined intervention for reasons unknown. Of those for whom clinical actions were indicated, 66% completed 3-month follow-up. Randomised controlled trial of the IBD-BOOST intervention: Participants ( N = 780) were randomised to the intervention ( n = 391) or care as usual ( n = 389). At 6 months, there were no statistically significant between-arm differences for United Kingdom Inflammatory Bowel Disease Questionnaire [mean difference = −1.67 (95% confidence interval = −4.17 to 0.83), p = 0.19] and Global Rating of Symptom Relief [mean difference = 0.44 (95% confidence interval = −0.56 to 1.43), p = 0.39]. Complier-averaged causal effects analysis demonstrated that participants who complied with the intervention reported better United Kingdom-Inflammatory Bowel Disease Questionnaire scores than ‘would-be’ compliers receiving care as usual ( p = 0.03). Subgroup analyses did not identify any statistically significant treatment effect modifiers; 57% completed four sessions or more. Serious adverse events were similar between groups. Process evaluation suggested high facilitator fidelity but low overall participant compliance with the programme. Cost-effectiveness of the IBD-BOOST intervention: Per participant cost for the development and delivery of intervention was £151.19. Allocation to inflammatory bowel disease-BOOST intervention resulted in additional 0.016 quality-adjusted life-years (95% confidence interval = 0.002 to 0.030) per participant over 12 months and cost savings of −£304.66 (−803.51; 194.18) for healthcare costs and −£39.48 (−388.09; 309.12) for out-of-pocket costs and time off work over months 3–6 and 9–12. Over the 12-month follow-up, there were cost savings of −£28,633 (95% confidence interval = −51,555 to 18,764) and −£33,568 (−64,421; 26,198) per quality-adjusted life-year gained with inflammatory bowel disease-BOOST from health services and societal perspectives, respectively. Limitations: Our samples were predominantly White and English-speaking. Conclusions: People with inflammatory bowel disease want help with their symptoms, but health professionals lack capacity. Over half of people with inflammatory bowel disease have faecal incontinence, and 1 in 10 have fatigue, pain and incontinence. Nearly a third want help for all three. Screening using a checklist and algorithm was feasible, and we identified around 40% who could benefit from optimisation of their medical treatment. Inflammatory bowel disease-BOOST had low compliance and did not improve disease-specific quality of life or Global Rating of Symptom Relief in inflammatory bowel disease patients with fatigue, pain and/or incontinence compared with care as usual, but it may help symptoms in people who comply with the programme. The economic evaluation indicated that the inflammatory bowel disease-BOOST intervention improves quality-adjusted life-years, and could be cost-effective, but economic results did not reach statistical significance. Future work: Research should explore targeting the intervention to specific subgroups within inflammatory bowel disease and improving adherence to digital interventions. Study registration: This study is registered as Optimising medical management ISRCTN15380317 and the RCT as ISRCTN71618461. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (NIHR award ref: RP-PG-0216-20001) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 19. See the NIHR Funding and Awards website for further award information.